BOTHELL, Wash., May 28 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has entered into a collaborative research agreement with Northwestern University's Feinberg School of Medicine to perform an acute myocardial infarction (AMI) disease model study in mice using CellCyte's CCG-TH30 product candidate. The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication. Douglas W. Losordo, M.D., a leader in cardiovascular cell therapy research and Director of Feinberg Cardiovascular Research Institute, will serve as the principal investigator on the study.
"We are extremely pleased to collaborate with Dr. Losordo, as he is one of the preeminent leaders in cardiovascular regenerative medicine," said Ronald W. Berninger, Ph.D., CellCyte's Chief Scientific Officer. "This is another important collaboration for our program, as it allows us to evaluate the functional outcome benefit of the CCG-TH30 therapy as compared to standard cell therapies where delivery agents aren't used."
About Douglas W. Losordo, M.D.
Dr. Losordo is a cardiologist at Northwestern Memorial Hospital and is the Director of Cardiovascular Regenerative Medicine and the Feinberg Cardiovascular Research Institute, both at Northwestern Memorial Hospital. He is board certified in Cardiovascular Disease, Internal Medicine, and Interventional Cardiology. Dr. Losordo is a member of the Northwestern Memorial Faculty Foundation, and his clinical interests include gene therapy, stem cell transplant, regenerative medicine and angiogenesis. He has preclinical expertise in animal models of cardiac disease, as well as preclinical and clinical expertise in stem cell therapy for cardiac regeneration. In recognition of his continued and outstanding achievements, Northwestern University's Feinberg School of Medicine named Dr. Losordo the Eileen M. Foell Professor of Heart Research in May 2007. He is a fellow of the American College of Cardiology, the American Heart Association, the American Association for the Advancement of Science, the American College of Physicians, the American College of Chest Physicians, and the Society for Cardiac Interventions and Angiography.
About Feinberg Cardiovascular Research Institute at Northwestern University
Originally established in 1988, the Feinberg Cardiovascular Research Institute is dedicated to pursuing an understanding of the fundamental molecular and cellular processes underlying cardiovascular disease, the largest contributor to morbidity and mortality in the United States. The mission of Feinberg Cardiovascular Research Institute is to improve the quality of human life through creative basic and translational research in cardiovascular disease, and to build a legacy of outstanding scholarship, scientific achievement, and therapeutic discovery. Investigators at Feinberg Cardiovascular Research Institute are exploring complex problems in modern cardiovascular research, including basic cellular signaling pathways and their contributions to disease, the use of stem cells in regenerative medicine, and diagnostic and imaging technologies critical to patient care.
About CellCyte Genetics
CellCyte Genetics Corporation is a biotechnology company engaged in the
discovery, development and commercialization of stem cell enabling
therapeutic products. CellCyte is developing products designed to allow
more efficient delivery and increased retention of adult stem cells to
diseased organs, such as the heart. The goal of these therapies is to
increase the number of stem cells delivered to a damaged organ, thereby
markedly increasing organ healing and functional restoration. The Company's
lead product in development, CCG-TH30, is designed to send autologous bone
marrow-derived (adult) stem cells to the heart of patients after a heart
For further information see: http://www.cellcyte.com .
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF CCG-TH30. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND COMPANIES, AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE.
|SOURCE CellCyte Genetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved